The IBB and SPX In The Decision Zone

In my previous report “IBB – A Closer Look at the Market’s Direction” I tried to find out if the markets bottomed out after the technical correction in the indices.

ONTY – Preparing For The Next Move

Oncothyreon Inc (ONTY)-Nasdaq Oncothyreon’s getting a lot of attention ahead of its near term catalyst set for Q1 2013 with the final analysis of its pivotal START trial. Results expected.

CLDX – A Positive Divergence Case

Celldex Therapeutics, Inc. (CLDX)-Nasdaq CLDX’s chart is one of a kind and very easy to understand even by a novice chart technician. It has been repeating the same moves, creating.

FOLD – Getting Ready For The New Uptrend

Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report.

IBB – A Closer Look at the Market’s Direction

In my previous report  “IBB – Nasdaq Biotechnology Index – Reaching a Critical Point ” I tried to find out if the technical correction in the index $IBB reached a.

IBB – Nasdaq Biotechnology Index – Reaching a Critical Point

iShares Nasdaq Biotechnology (IBB)-NasdaqGM Typically, the best indicator of the action in our biotech portfolio is the $IBB. By looking at it we get the whole picture of the pressure.

ACAD – The Last Run to The Parkinson’s Disease Psychosis Results

ACADIA Pharmaceuticals Inc. (ACAD) -NasdaqGM Catalyst: late Nov. P-III results for Parkinson disease Acadia reported a 100% patient enrollment on Sep 05th: ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase.

CPRX – Volatility Squeeze Ahead of The Tope-Line Results

Catalyst Pharmaceutical Partners Inc. (CPRX) -NasdaqCM Catalyst: Phase IIb trial results Sentiment : Bullish This report is supplement to the thorough report by Jason Chew, release earlier this week. In.

EXEL – Looking for Direction Ahead of the PDUFA date

Exelixis (NASDAQ: EXEL) On 5/30/12, Exelixis submitted their NDA for Cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). They were subsequently.

BMRN – A Busy Quarter Ahead.

BioMarin (NASDAQ:BMRN) $BMRN is a ticker that every biotech investor or trader would like to see it in his portfolio. Just look at the weekly chart to understand the huge.

INCY – Is It A Good Time To Start A Position?

Incyte Corporation (INCY) The chart of INCY pop up in my chart screener, as a chart with a bullish reversal pattern called “Tripple Bottom” . The Triple Bottom Reversal is.

ZIOP – Trading In an Uptrend Channel

Ziopharm(NASDAQ: ZIOP) In Patrick’s latest article “Smallcap Phase 3 data expected by year-end 2012” he mentions Ziopharm’s current Phase 3 trial of Palifosfamide. This Phase 3 trial, known as PICASSO 3,.

EXEL – In A Consolidation Mode

EXEL “Exelixis” had an impressive uptrend starting in June 2012, anticipating the FDA reply for the NDA filling & priority review, starting from the $4.40 area, reaching the $6.95 point.

Browsing 13 / articles